Feasibility study of Barrier Enhancement for Eczema Prevention: a multicentre, assessor-blinded, randomised controlled trial

ottingham University Hospitals NHS Trust (UK)0 个研究点目标入组 200 人开始时间: 2010年2月26日最近更新: 2019年2月11日

适应症

试验速览

•UK and USA:
•1. Infants with a family history of eczema, asthma or allergic rhinitis
•2. Infant in overall good health
•3. Mother aged between 16 and 45 years at delivery and capable of giving informed consent

•UK and USA:
•1. Preterm birth (defined as birth prior to 37 weeks gestation)
•2. Major congenital anomaly
•3. Hydrops fetalis
•4. Significant dermatitis at birth not including seborrheic dermatitis (?cradle cap?) (added 13/07/2010)
•5. Any severe genetic skin disorder or immunodeficiency
•6. Any other serious condition that would make the use of emollients inadvisable
•7. Any other major medical problems that the investigator deems may increase the risk of adverse events with the intervention or in whom assessing the outcomes may be masked by the underlying problem or practically very difficult to assess
•8. Taken supplements containing Lactobacillus Rhamnosus during pregnancy or plan to take whilst lactating (added 13/07/2010)

发起方

ottingham University Hospitals NHS Trust (UK)